Loxo Oncology, Inc. (NASDAQ:LOXO) was founded in 2013 and is headquartered in Stamford, Connecticut, USA, with 22 full-time employees. It mainly develops new drugs for small molecule targeted drugs for cancer treatment.
Loxo Oncology (LOXO):
LOXO is a new drug development company that mainly develops small molecule targeted drugs for cancer/tumor treatment. Its core product: LOXO-101, is an oral or selective tyrosine kinase receptor inhibitor. It is currently in phase I clinical trials. It is used to treat advanced tumor conditions, including: neurocytoma, lung cancer, and thyroid Cancer, breast cancer, etc.
In addition, Loxo Oncology also develops other product projects for cancer patients who have metastasized through genetic pathways.
Loxo and Array BioPharma Inc. signed a “drug development cooperation agreement” to obtain multiple rights to TRK (tropomyosin receptor kinase) inhibitor programs and tumor indicators.
Loxo Oncology and Bayer are distributors of Vitrakvi (larotrectinib), a newly approved cancer treatment drug approved by the FDA.
In January 2019, Eli Lilly and Company announced that it had agreed to acquire Loxo Oncology, Inc. for USD 8 billion.
Loxo Oncology (LOXO) investment:
Has been acquired and will be delisted soon.